| | | | |

NIH AIDS Research Chief Rewrote Safety Report – AP

NIH AIDS Research Chief Rewrote Safety Report – AP Wed, 15 Dec 2004 John Solomon of The Associated Press continues his documented expose of the inner workings of the AIDS Division of theNational Institutes of Health (NIH). At the same time that the Los Angeles Times and Congfressional hearings focused…

Consumers Union launches "Prescription for Change" drug information Campaign

Consumers Union launches “Prescription for Change” drug information Campaign Mon, 13 Dec 2004 The Alliance for Human Research Protection applauds Consumers Union for joining and amplifying our efforts to promote open access and full disclosure of research information affecting the health and welfare of consumers young and old. Specifically, Consumers…

Hoffman LaRoche Rebuffed Call to Monitor Accutane Users – USA Today

Hoffman LaRoche Rebuffed Call to Monitor Accutane Users – USA Today Tue, 7 Dec 2004 An investigative cover story in USA Today – Drugmaker Rebuffed Call to Monitor Users–affirms the indispensable role of litigation in bringing the facts about adverse drug effects to public knowledge. Lawsuits against Hoffman-La Roche, manufacturer…

Credibility Crisis: Survey FDA Scientists – Death in NIH-AIDS Trial – Tauzin Moves to PhRMA

Credibility Crisis:Survey FDA Scientists – Death in NIH-AIDS Trial – Tauzin Moves to PhRMA Thu, 16 Dec 2004 A credibility crisis in medical research is smoldering: like the Enron accounting scandal, the prescription-drug debacle is a matter of systemic corruption, including gross and widespread failure by the regulatory process. Unlike…

FDA Approves Lilly’s Cymbalta for Depression Despite Risk of Suicide

FDA Approves Lilly’s Cymbalta for Depression Despite Risk of Suicide Wed, 4 Aug 2004 In a display of arrogance and defiance–in the midst of federal investigations into the marketing of antidepressants–the FDA has approved Eli Lilly’s antidepression drug, Cymbalta (duloxetine). Lilly’s press release announced: “Cymbalta, a balanced and potent reuptake…

Drug safety Hearings-Sept-Congress/ FDA – Lilly Plans to Disclose Data

Drug safety Hearings-Sept-Congress/ FDA – Lilly Plans to Disclose Data Tue, 3 Aug 2004 A hearing about the possible connection between suicide and antidepressant drugs will be held on Aug 4, by the California Senate by Sen. Tom Torkalson, chairman of the Senate Task Force on Youth and Workplace Wellness…

Spitzer Expands drug Probe: Johnson & Johnson / New FDA analysis Confirms SSRI Risks to Kids – WSJ

Spitzer Expands drug Probe: Johnson & Johnson / New FDA analysis Confirms SSRI Risks to Kids – WSJ Thu, 5 Aug 2004 A front page article in The Wall Street Journal reports that a second FDA analysis of 25 clinical trials of SSRI antidepressants in children was conducted after a…

Time for a Drug Test Registry_Marcia Angell_Why NIH is Not Up to the Task

Time for a Drug Test Registry_Marcia Angell_Why NIH is Not Up to the Task Fri, 13 Aug 2004 The uncovering of concealed, unpublished evidence showing that children suffered harm in antidepressant drug trials, has led to a rude public awakening. Selective reporting of clinical trial data has become “standard practice”…